The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
本发明提供了化合物、其组合物以及使用这些化合物来抑制TYK2并治疗TYK2介导的疾病的方法。
Palladium-Catalyzed sp<sup>3</sup> C—H Activation of Simple Alkyl Groups: Direct Preparation of Indoline Derivatives from <i>N</i>-Alkyl-2-bromoanilines
The sp3 C-H activation of a simple alkyl group catalyzed by palladium(0) provides a novel and convenient strategy for the synthesis of various indolinesfrom simple precursors, such as N-alkyl-2-bromoanilines. This study demonstrates that assisting moieties in the substrate such as a pyridine or quaternary carbon are not always necessary for sp3 C-H activation.
[EN] TYK2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE TYK2 ET LEURS UTILISATIONS
申请人:NIMBUS LAKSHMI INC
公开号:WO2016138352A1
公开(公告)日:2016-09-01
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
Intramolecular Palladium-Catalyzed Alkane C−H Arylation from Aryl Chlorides
作者:Sophie Rousseaux、Michaël Davi、Julien Sofack-Kreutzer、Cathleen Pierre、Christos E. Kefalidis、Eric Clot、Keith Fagnou、Olivier Baudoin
DOI:10.1021/ja1048847
日期:2010.8.11
efficient and general palladium-catalyzed intramolecular C(sp(3))-H arylation of (hetero)aryl chlorides, giving rise to a variety of valuable cyclobutarenes, indanes, indolines, dihydrobenzofurans, and indanones, are described. The use of aryl and heteroaryl chlorides significantly improves the scope of C(sp(3))-H arylation by facilitating the preparation of reaction substrates. Careful optimization studies
[EN] NOVEL COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS<br/>[FR] NOUVEAUX COMPOSÉS DESTINÉS AU TRAITEMENT DE LA MUCOVISCIDOSE
申请人:NIVALIS THERAPEUTICS INC
公开号:WO2015143376A1
公开(公告)日:2015-09-24
The present invention is directed to novel compounds, pharmaceutical compositions comprising such compounds, and the methods of making and using the same. These compounds are useful as modulators of Cystic Fibrosis Transmembrane Conductor Regulator (CFTR). The present invention also relates to methods of treating or lessening the severity of cystic fibrosis in a patient. These compounds may be used alone or in combination with one or more secondary active agents.